Background {#s1}
==========

Coronaviruses, belonging to the family Coronaviridae, are positive-sense enveloped RNA viruses that cause infections in humans ([@B31]; [@B22]). The family includes four genera (Alphacoronavirus, Betacoronavirus, Deltacoronavirus, and Gammacoronavirus). The genus Betacoronavirus includes severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Historically, these coronaviruses had got great clinical importance in infecting humans ([@B21]). At present, the novel coronavirus strain, the SARS-CoV-2, the causative agent of COVID-19 emerged in Wuhan, China, in December 2019 ([@B35]). Since then, the number of cases and deaths related to this virus have been skyrocketing throughout the world.

As per the World Health Organization (WHO) report, the total number of cases and deaths outside China has overtaken the total number of cases in China ([@B32]). WHO has declared COVID-19 worldwide pandemic and global public health emergency with Europe and lately Unites States of America became new epicenters. WHO has recommended several preventive measures including laboratory tests for any suspected cases, quarantining suspects, applying physical distancing, frequent hand washing, and using hand and surface sanitizers to help contain further spread of the pandemic ([@B32]). Despite such preventive strategies, there is no vaccine or drug therapy officially approved for prophylaxis or treatment of COVID-19. At present, there are several classes of drugs undergoing clinical trials including RNA polymerase inhibitors (remdesivir and favipiravir), protease inhibitors (lopinavir/ritonavir), aminoquinolines (chloroquine and its hydroxyl derivative), anti-inflammatory agents (corticosteroids, and xiyanping injection), angiotensin converting enzyme type 2 blockers, convalescent plasma, viral RNA antisense technologies, monoclonal antibodies, and Chinese traditional medicines (<http://www.chictr.org.cn/index.aspx> and <https://clinicaltrials.gov/ct2/home>).

Overview of Other Frontline Antiviral Agents Under Extensive Clinical Investigation {#s2}
===================================================================================

Among the above-mentioned classes of antiviral counterparts, aminoquinolines (chloroquine and its hydroxyl derivative) and protease inhibitors (primarily lopinavir/ritonavir) have taken the largest share of clinical trials since the SARS-CoV-2 outbreak. However, their clinical benefit has become full of controversies according to the various research findings.

With regard to the aminoquinolines and their role in COVID-19 therapy, in an open-label non-randomized clinical trial, Gautret et al. reported 100% viral clearance in nasopharyngeal swabs with combination of hydroxychloroquine and azithromycin, 57.1% in hydroxychloroquine group, and 12.5% in standard of care group in cohort of 6 patients after 5 to 6 days follow-up ([@B13]). In addition, in study conducted in 62 patients in China, the use of hydroxychloroquine could significantly shorten the time to clinical recovery and promote the absorption of pneumonia in randomized open label clinical trial ([@B8]). In contrary to this, a recent study from China in individuals with COVID-19 found no difference in the rate of virologic clearance at 7 days with or without 5 days of hydroxychloroquine, and no difference in clinical outcomes ([@B7]) indicating the absence of evidence of a strong antiviral activity (rapid viral clearance) or clinical benefit of this combination for severe COVID-19 patients. Another randomized open label clinical trial posted on MedRxiv (preprint) reported that the overall 28-day negative conversion rate and symptoms alleviation rate in hydroxychloroquine plus standard of care group was not different from standard of care group ([@B27]). Apart from this, the safety issues of aminoquinolines should also be emphasized. The cardiovascular and retinal toxicities may also limit the usefulness of these agents if there is hope from ongoing randomized, blinded and placebo controlled trials. For example, the hydroxychloroquine and azithromycin have shown to prolong QT-interval resulting torsades de pointes (a form of polymorphic ventricular tachycardia) and sudden cardiac death ([@B9]).

A randomized, open label clinical trial conducted on protease inhibitors (lopinavir/ritonavir) indicated that treatment with lopinavir/ritonavir did not show statistically significant difference in the time to clinical improvement and mortality censored at day 28 though a secondary outcomes measures were found promising in lopinavir/ritonavir group ([@B4]). This trial was initiated in severe COVID-19 patients lately and lacks blinding and well established placebo.

Remdesivir is one of the frontline medications being used as expanded access and is under extensive clinical investigation. Hereafter, this review aims to address the viral polymerase inhibitor remdesivir as a potential therapeutic option for COVID-19.

Remdesivir: Chemistry and Mechanism of Action {#s3}
=============================================

Remdesivir (GS-5734™) is a phosphoramidate prodrug of a Pyrrolo\[2,1-*f\]*\[triazin-4-amino\] adenine **C***-*nucleoside having broad spectrum antiviral activity ([**Figure 1**](#f1){ref-type="fig"}). Remdesivir is metabolized into its active form, GS-441524, that interferes with viral RNA dependent RNA polymerase (RdRp) enzyme thereby it evades proofreading by viral exonuclease, and arrests RNA synthesis. This drug has shown potent inhibitory activity against RdRp with intact proof reading and with low level of resistance to target mutations ([@B1]). It is supported in the study conducted by Gordon et al. who demonstrated RdRp is, indeed, the target of remdesivir in MERS-CoV strains ([@B17]). Studies based on the molecular dynamics simulation and free energy perturbation methods clearly indicated SARS-CoV-2 RdRp as a target of remdesivir ([@B34]). Though, it has not been officially approved for Ebola and Coronaviruses yet ([@B26]), Gilead Sciences is working closely with organizations and health authorities to respond to the COVID-19 outbreak through synthesizing and providing this investigational drug ([@B14]).

![Structure and metabolic conversion of remdesivir.](fphar-11-00791-g001){#f1}

Evidence on Its *in Vitro* Activity {#s4}
===================================

Agostini et al. demonstrated that remdesivir can potently inhibit coronaviruses such as SARS-CoV-1 and MERS-CoV *in vitro* ([@B1]). Remdesivir can inhibit SARS-CoV-1 and MERS-CoV replication in several *in vitro* systems, including primary human airway epithelial cell cultures ([@B24]). In research conducted by Sheahan et al, remdesivir showed superior antiviral activity to lopinavir/ritonavir against MERS-COV *in vitro* ([@B25]). In MERS-COV nonstructural proteins (nsp5, nsp7, nsp8, and nsp12) of insect cell lines, remdesivir showed potent inhibitory activity against nsp12(RdRp) *in vitro* ([@B17]). Yethindra et al. demonstrated that remdesivir showed strong inhibition against SARS-CoV and MERS-CoV in human air way epithelial cells, at early stages in replication process *via* inhibiting viral RNA synthesis ([@B33]). On the top of these, remdesivir has shown promising results in clinical control of SARS-CoV-2 pneumonia *in-vitro* in human liver cancer cell lines ([@B29]). Beyond Beta-CoVs, remdesivir has shown potent inhibition of human endemic and zoonotic Delta-CoVs with highly divergent RdRp in human hematoma (huh7) cell lines ([@B3]).

Evidence on *in Vivo* Antiviral Activity {#s5}
========================================

In a mouse model of SARS-CoV-1, prophylactic and therapeutic (at early stage) administration of remdesivir significantly reduced pulmonary viral load and improved respiratory function and other clinical signs of the disease ([@B24]). Likewise, both prophylactic and therapeutic remdesivir has shown improvement on the pulmonary function and reduced lung viral loads and severe lung pathology in MERS-COV strains in mice model ([@B25]). In the rhesus macaque model of MERS-CoV infection, remdesivir reduced virus replication, the severity of the disease, and lung damage when administered in animals infected with MERS-CoV ([@B11]). Despite having an *in-vitro* antiviral activity against SARS-CoV-2, there are no published studies justifying the activity of remdesivir in animal models of SARS-CoV-2 *in vivo* until the time of this review.

Case Report {#s6}
===========

According to the paper published at the New England Journal of Medicine on 05 March, 2020, it had been suggested that remdesivir might be a potential therapeutic option for the therapy of COVID-19 patients. In the report, remdisivir intravenous infusion (compassionate use) was started on day 7 in COVID-19 patient. During the treatemnt, no adverse events were observed in association with the IV infusion. The patient\'s clinical condition improved. The bilateral lower-lobe rales apeared initially were no longer present. His appetite improved, became afebrile and asymptomatic except intermittent dry cough and rhinorrhea ([@B19]). However, this is a single patient report and is too infant to conclude its efficacy and disentangle the true effect size of this drug because of the chance of recovery from this disease without treatment(s). Hence, it is imperative to have adequate, well controlled, randomized, and blinded clinical trials in large cohorts of patients to justify its clinical utility in real settings.

Ongoing Clinical Trials and Future Prospects {#s7}
============================================

As summarized in [**Table 1**](#T1){ref-type="table"}, Gilead Sciences has initiated two phase 3 randomized, open label clinical trials comprising approximately 1,000 COVID-19 patients. In the first trial, 400 patients with severe COVID-19 cases were enrolled to evaluate the safety and efficacy of remdesivir on 5 (Arm 1) and 10 days (Arm 2) regimens with standard of care in both arms without comparator ([@B15]). In the second trial, 600 patients with moderate COVID-19 cases were enrolled to evaluate the safety and efficacy of the same dosage regimen of remdesivir in addition to the standard of care and with standrad of care alone as active comparator ([@B16]).

###### 

Ongoing clinical trials registered under United States National Library of Medicine clinical trials registry and addressing the safety and efficacy of remdesivir (GS-5734™) as a potential therapeutic option for COVID 19.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical trial identifier   Study design                                                  Estimated\                               Phase of the study   Conditions                             Interventions                                                                   Primary outcome measures                                        Recruitment status                                                                                                        
                                                                                            enrollment                                                                                                                                                                                                                                                                                                                                                                     
  --------------------------- ------------------------------------------------------------- ---------------------------------------- -------------------- -------------------------------------- ------------------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- --------------------
  NCT04292899\                Randomized, open label clinical trial                         400                                      Phase 3              Severe\                                **Arm 1:** Remdesivir IV infusion for 5 Days + standardized care\               **Active:** No placebo                                          Composite outcome measure (proportion of participants with normalization of fever and oxygen saturation through day 14)   Recruiting
  ([@B15])                                                                                                                                                COVID 19                               **Arm 2**: Remdesivir IV infusion 10 Days                                                                                                                                                                                                                                 

  NCT04292730\                Randomized, open label clinical trial                         600                                      Phase 3              Moderate COVID 19                      **Arm 1:** Remdesivir IV infusion for 5 Days + standardized care\               **Arm 3:** Active\                                              Proportion of participants discharged by day 14                                                                           Recruiting
  ([@B16])                                                                                                                                                                                       **Arm 2:** Remdesivir IV infusion 10 Days                                       (Standard of Care)                                                                                                                                                                        

  NCT04252664\                Randomized, Double-blind, Placebo-controlled clinical trial   308                                      Phase 3              Mild and Moderate COVID 19             **Arm 1:** Remdesivir IV for 10 Days\                                           **Arm 2**: Placebo that match remdesivir in dose and duration   Time to clinical recovery (TTCR) Upto 28 days                                                                             Recruiting
  ([@B5])                                                                                                                                                                                        (200 mg loading dose for day 1 followed by 100 mg IV for 9 days)                                                                                                                                                                                                          

  NCT04257656\                Randomized, Double-blind, Placebo-controlled clinical trial   453                                      Phase 3              Severe\                                **Arm 1:** Remdesivir IV for 10 Days\                                           **Arm 2:** Placebo that match remdesivir in dose and duration   Time to Clinical Improvement (TTCI) \[Censored at Day 28\]                                                                Completed
  ([@B6])                                                                                                                                                 COVID 19                               (200 mg loading dose for day 1 followed by 100 mg IV for 9 days)                                                                                                                                                                                                          

  NCT04280705\                Adaptive, Randomized, double Blind Controlled Trial           394 (1:1)                                Phase 3              Hospitalized patients with COVID 19\   **Arm 1:** 200 mg RDV IV for day 1 followed by 100 mg IV QD for 9 days          **Arm 2**: Placebo that match remdesivir in dose and duration   Percentage of subjects reporting each severity rating on the 7-point ordinal scale within 15 days                         Recruiting
  ([@B23])                                                                                                                                                (no specific severity)                                                                                                                                                                                                                                                                                           

  NCT04302766\                Expanded access                                               General (Intermediate-size Population)   NA                   Any COVID 19 case                      Not stated                                                                      Not stated                                                      NA                                                                                                                        Available
  ([@B28])                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  NCT04315948\                Adaptive, Randomized, Open label clinical Trial               3200                                     Phase 3              COVID-19\                              **Arm 1:**\                                                                     **Arm 4:** (Active)\                                            Percentage of subjects reporting each severity rating on a 7-point ordinal scale within 15 days                           Not yet recruiting
  **(DisCoVeRy trial**)\                                                                                                                                  in hospitalized adults                 200 mg RDV IV for day 1 followed by 100 mg IV QD for 9 days\                    Standard of care                                                                                                                                                                          
  ([@B20])                                                                                                                                                                                       **Arm 2:**\                                                                                                                                                                                                                                                               
                                                                                                                                                                                                 Lopinavir/ritonavir (400 mg/100 mg) tablet BID for 14 days\                                                                                                                                                                                                               
                                                                                                                                                                                                 **Arm 3:**\                                                                                                                                                                                                                                                               
                                                                                                                                                                                                 Lopinavir/ritonavir (400 mg/100 mg) tablet BID for 14 days plus\                                                                                                                                                                                                          
                                                                                                                                                                                                 Interferon ß-1a 44 ug subcutaneously in total of three doses (Day 1, 3 and 6)                                                                                                                                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

With the coordination of China-Japan Friendship Hospital, two phase 3 randomized, double blind, placebo controlled clinical trials were intiated in China to evaluate the safety and efficacy of remdesivir paralleled to palcebo therapy.The first phase 3 trial has already involved 308 hospitalized adult patients with mild to moderate cases of COVID-19 ([@B5]). The patients were randomized to intervention arms of either remdesivir 10 days regimen or placebo that matched to remdesivir. The primary end point of this trial is set to determine the time to clinical recovery (TTCR) within 28 days. Another phase 3 randomized, double-blind, placebo-controlled trial is evaluating the safety and efficacy of 10 days of remdesivir regimen in 453 hospitalized adult patients with severe COVID-19 compared to placebo matched to remdesivir in dose and duration. The primary outcome measure in this trial is the time to clinical improvement (TTCI) censored at day 28 ([@B6]) ([**Table 1**](#T1){ref-type="table"}). At the time of this revision, the finding of the second trial was published on Lancet. Though not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (Hazard ratio 1.52 \[0.95--2.43\]). In addition, remdesivir did not show statistically significant clinical benefits ([@B30]). However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in the larger cohort of patients and in the remaining trials

With the coordination of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), Another phase 3 adaptive, randomized, double blind, placebo controlled clinical trial enrolled 394 hospitalized patients with COVID-19 to assess the safety and efficacy of remdesivir. In this trial, patients were randomized to either placebo or 10 days therapy with remdesivir (200 mg remdesivir IV loading dose for day 1 followed by 100 mg IV daily maintained for 9 days, total of 10 days therapy). The primary indicator in this trial is the percentage of patients reporting each severity rating on the 7-point ordinal scale within 15 days ([@B23]) ([**Table 1**](#T1){ref-type="table"}).

With the sponsor and coordination of U.S. Army Medical Research and Development Command (AMRDC), remdesivir is also provided as expanded access (compassionate use) ([@B28]) through emergency investigational new drug applications. The term expanded access (compassionate use) is a potential pathway in which a patient with an immediately life-threatening condition or disease gain access to an investigational medical product for treatment of patients outside of clinical trials when no comparable or satisfactory alternative therapy options are available ([@B12]). To this end, remdesivir synthesized and developed by Gilead Sciences is readily available for compassionate use for COVID-19 patients ([@B10]) ([**Table 1**](#T1){ref-type="table"}). Latest observational study published on The New England Journal of Medicine revealed that severe Covid-19 patients treated with compassionate-use of remdesivir showed clinical improvement in 68% cases ([@B18]).

On the top of this, WHO has initiated Solidarity trial at global level to evaluate the safety and efficacy of remdesivir in one of the interventional arms ([@B2]). Likewise, National Institute of Health and Medical Research (INSERM) of France has planned to initiate DisCoVeRy trial ([@B20]). The trial protocol has already been registered on 20 March, 2020 and available at <https://clinicaltrials.gov/ct2/show/NCT04315948>. The recruiting of participants has not been started but estimated to enroll 3,200 patients in 4 arms in which remdesivir alone is to be provided in usual dosage regimen in one of the interventional arms.

Conclusion {#s8}
==========

Despite the promising effects of remdesivir against previous beta-coronaviruses as well as the current novel coronaviruses *in vitro*, there is no published *in vivo* study that substantiates the *in vitro* activities against this global public health threat. A case report and observational studies are not sufficient to generate evidenced-based medicine on the clinical use of remdesivir for this pandemic. A double blind, placebo controlled randomized clinical trial showed that remdesivir did not have statistically significant clinical benefit in reducing the time to clinical improvement in severe COVID-19 patients compared to placebo. Though remdesivir is readily available for compassionate use in many countries, it is imperative to wait the remaining ongoing clinical trials to justify its clinical utility on larger cohort of COVID-19 patients.
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